Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Asahi Brewery discloses antioxidants

June 21, 1996

Schering AG claims AMPA antagonists for neurodegenerative disorders

June 21, 1996

Hoechst synthesizes NOS inhibitors

June 21, 1996

Approval of Daiichi's Translon imminent

June 21, 1996

Conflicting studies on besipirdine

June 21, 1996

5-HT1A agonist for cognition disorders disclosed

June 21, 1996

Alzheimer's beta-protein inhibition method described

June 21, 1996

Cholinergic agonists claimed by Lilly

June 21, 1996

Anergen's MS-AnergiX enters phase I for MS

June 21, 1996

Agents for multiple sclerosis disclosed

June 21, 1996

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...